Arabidopsis thaliana-also known as thale cress or mouse-ear cress-grows abundantly in cracks in pavements all over Europe and Asia, but the small white flower leads a second life as the lab rat of the plant world.
It has become the dominant model plant in genetics research because of its simple genetics and ease of use in a research environment. Thousands of trays of the humble weed are cultivated in laboratories across the world, but it turns out they may actually contain a rather oddball plant.
A study by researchers at the University of Leeds found that Arabidopsis thaliana was exceptional in not having a key "censorship" protein called SMG1.
SMG1 was known to play a vital role in the growth of animals as multicellular organisms, but scientists thought that plants built their complex life fundamentally differently. That conclusion, it turns out, was built on a dummy sold by Arabidopsis thaliana.
Professor Brendan Davies from the University of Leeds' School of Biology, who led the study, said: "Everybody thought that this protein was only in animals. They thought that because, basically, most of the world studies one plant: Arabidopsis thaliana."
Gene expression-the process by which the information from a genome is converted into the differentiated cells that make up complex life-relies on processes that turn genes on, when their genetic messages are required, and off when they are not.
"Switching genes on and off is really what life is about. If you can't do that, you can't have life," said Professor Davies. "There are various ways this is done, but one way in more complex life such as animals and plants is through a sort of 'censorship' process. The system looks at the messages that come out of the nucleus and effectively makes a judgement on them. It says 'I am going to destroy that message now' and intervenes to destroy it before it takes effect."
Scientists know that this "censorship" process-called Nonsense Mediated mRNA Decay (NMD)-is used by both plants and animals, but thought the two types of organism did it in different ways. Because Arabidopsis thaliana does not have SMG1, which plays a key role in triggering the censorship system in animals, scientists had concluded that SMG1 was not present in any plant.
However, the Leeds researchers discovered that the plant that has established itself as the standard reference plant for all of biology is in fact an anomaly.
"We have found that SMG1 is in every plant for which we have the genome apart from Arabidopsis and we have established that it is being used in NMD. Rather than being just in animals, we are suggesting that the last common ancestor of animals and plants had SMG1," Professor Davies said.
The study also found SMG1 in Arabidopsis lyrata, a close relative of Arabidopsis thaliana, which suggests that the missing protein has been lost relatively recently in evolutionary time, perhaps in the last 5-10 million years.
The next key question for researchers is to explain how organisms without SMG1, such has funghi and Arabidopsis thaliana, work without the protein.
As for Arabidopsis thaliana, it may not have met its Waterloo just yet. "It is still a fantastically useful model. We would not be anywhere close to where we are in understanding plant biology without it, but this is a lesson to us all about the dangers of extrapolating from a single model, however successful that model has been, and the importance of studying processes in a range of models. Evolution does strange and unpredictable things," Professor Davies said.
The flower, which is a member of the mustard family, was first recorded by Johannes Thal in the Harz mountains of northern Germany in the 16th century, but its scientific career really took off at the very end of the 1970s and the early 1980s when molecular geneticists chose it as the ideal model.
Its simple genome, small size, ease of cultivation, and rapid life cycle have since made it an institution in plant genetics with books, web sites and academic conferences devoted to it. In 2008 alone, 3,500 papers on Arabidopsis thaliana were added to the PubMed database, which logs important publications in the life sciences.
The plant has a history of leaving scientists scratching their heads. In the 18th century, it was categorised as one of the Arabis genus but had to be renamed "Arabidopsis," meaning "resembling Arabis" after the original classification was found to be incorrect.
The paper, published in The Plant Journal, was co-authored by Professor Davies and University of Leeds PhD student James Lloyd. The research was funded by a grant from the Gatsby Charitable Foundation.
Nic Stonehouse, MRC (Mar 2017), £906,341
Bill Kunin, BBSRC (Mar 2017), £602,831
Adrian Goldman, EU (Mar 2017), £546,576
Sheena Radford, Wellcome Trust (Mar 2017), £1,836,482
Beatrice Filippi, Royal Society (Mar 2017), £15,000
Jamie Johnston, Royal Society (Mar 2017), £15,000
Tom Bennett, Royal Society (Mar 2017), £15,000
Ryan Seipke, BBSRC (Feb 2017), £52,116
Mary O'Connell, BBSRC (Feb 2017), £46,986
Hannah Dugdale, NERC (Feb 2017), £504,138
Anastasia Zhuravleva, EPSRC (Jan 2017), £100,792
Richard Bayliss, Cancer Research UK (Jan 2017), £1,600,000
John Barr, EU (Jan 2017), £339,000
Mark Harris, Royal Society (Jan 2017), £250,000
Alison Dunn, NERC (Jan 2017), £105,000
Alex Breeze, Pancreatic Cancer Research Fund (Jan 2017), £180,000
Alison Dunn, NERC (Dec 2016), £18,000
Lisa Collins, BBSRC (Dec 2016), £1,681,835
Brendan Davies, Leverhulme Trust (Dec 2016), £247,555
Alan Benson, Mark Drinkhill, Ed White, British Heart Foundaion (Dec 2016), £217,223
Adrian Goldman, Royal Society (Dec 2016), £82,999
Lisa Roberts, Alex Breeze, Brendan Davies, Timothy Devinney, Oliver Harlen, Joseph Holden, Anthea Hucklesby, Pamela Jones, Philip Mellor, RCUK (Nov 2016), £484,172
Lisa Roberts, Alex Breeze, Brendan Davies, Timothy Devinney, Oliver Harlen, Joseph Holden, Anthea Hucklesby, Pamela Jones, Philip Mellor, Wellcome Trust (Nov 2016), £119,343
Katie Field, Rank Prize Funds (Nov 2016), £20,000
Jessica Kwok, Royal Society (Nov 2016), £14,948
John Ladbury, Cancer Research UK (Oct 2016), £4,250
Miriam Wittmann, Martin Stacey, Edward Vital, Lupus UK
(Oct 2016), £34,010
Valerie Speirs, NC3Rs
(Oct 2016), £90,000
Nicola Stonehouse, Morgan Herod, David Rowlands, BBSRC
(Sep 2016), £436,424
Joseph Cockburn, Wellcome Trust
(Sep 2016), £100,000
John Barr, Public Health England
(Sep 2016), £94,471
Helen Miller, DSM Nutritional Products A/S
(Sep 2016), £54,680
Steven Clapcote, Vitaflo International Ltd
(Sep 2016), £39,285
Juan Fontana Jordan De Urries
, Royal Society
(Sep 2016), £21,793
Jing Li, Sarah Calaghan, Mark Drinkhill, British Heart Foundation
(Sep 2016), £117,585
Sheena Radford, Alison Ashcroft, BBSRC (Sep 2016), £457,216
Patricija Van Oosten-Hawle, An-Jung Chen, David Westhead, NC3Rs
(Sep 2016), £354,456
Glyn Hemsworth, BBSRC (Sep 2016), £1,024,034
David Jayne, Paul Millner, MRC (Aug 2016), £207,860
Sheena Radford, Alison Ashcroft, BBSRC (Aug 2016), £457,215
Patricija Van Oosten-Hawle, Dave Westhead, An-Jung Chen, NC3Rs (Aug 2016), £354,456
Peter Henderson, EU - European Union
EU - European Union
(Jul 2016), £123,897
Adrian Goldman, EU - European Union
(Jul 2016), £116,290
Urwin, Howard Atkinson, NERC
(Jul 2016), £105,053
Eileen Ingham and colleagues in Engineering and M&H, EPSRC (Jul 2016), £3,867,449
Michael Colman, MRC (Jul 2016), £200,956
Tim Benton, Fresca Group Ltd
(Jul 2016), £52,082
Derek Steele, Sarah Calaghan, Chris Peers, BHF (Jul 2016), £819,241
Paul Millner and colleagues in Engineering and M&H, BBSRC (Jul 2016), £129,647
Vas Ponnambalam, Darren Tomlinson, Stephen Wheatcroft, BHF (Jul 2016), £107,359
John Colyer, Christian Teade and colleagues in M&H, Kidney Research Fund UK (Jul 2016), £39,964
Nicola Stonehouse, David Rowlands, World Health Organisation (Jul 2016), £656,545
Alexander Breeze, MRC
(Jul 2016), £403,513
Yoselin Benitez-Alfonso and colleagues in MaPS, Leverhulme Trust (Jul 2016), £353,301
Joan Boyes, Peter Stockley, Roman Tuma, David Westhead, Bloodwise (Jul 2016), £232,960
Edwin Chen, Leuka
(Jul 2016), £98,642
Helen Miller, Hamlet Protein A/S
(Jul 2016), £22,240
Alexander Breeze, Syngenta
(Jul 2016), £299,629
Alan Berry, Wellcome Trust
(Jul 2016), £599,375
Amanda Bretman, Elizabeth Duncan, Leverhulme Trust
(Jul 2016), £245,369
Andrew Macdonald, Neil Ranson, Richard Foster, Yorkshire Kidney Research Fund (Jul 2016), £51,368
Roman Tuma, Sheena Radford, BBSRC
(Jul 2016), £379,786
Adrian Whitehouse, Ian Carr, Worldwide Cancer Research (Jul 2016), £199,738
Paul Milner, Mike McPherson, Lars Jeuken, Darren Tomlinson and colleagues in Engineering & M&H, MRC (Jul 2016), £3,124,568
Helen Miller, Innovate UK (Jun 2016), £3,463,470
Adrian Goldman, Royal Society
(Jun 2016), £250,000
Jim Deuchars, Susan Deuchars, Shaunna Burke, Dunhill Medical Trust (Jun 2016), £86,570
Keith Hamer, Guy Ziv, DEFRA Dept for Env. Food & Rural Affairs
(Jun 2016), £300,122
Richard Bayliss, EU - European Union
(Jun 2016), £373,565
Sheena Radford, Eric Hewitt, Alison Ashcroft, Andrew Wilson, EPSRC (Jun 2016), £458,278
Jamel Mankouri, John Barr, British Lung Foundation
(Jun 2016), £24,000
Zahrah Timsah, Wellcome Trust (Jun 2016), £100,000
Andrew Macdonald, Kidney Research Fund UK
(Jun 2016), £63,653
Edwin Chen, Academy of Medical Sciences
(Jun 2016), £98,110
Adrian Goldman, Royal Society (May 2016), £250,000
Peter Stockley, Wellcome Trust (May 2016), £1,246,487
John Ladbury, Christopher Jones, Cancer Research UK
(May 2016), £6,905
Elton Zaqiraj, Wellcome Trust (May 2016), £1,093,823
Alison Baker, Miller Camargo-Valero, BBSRC
(May 2016), £553,691
Adrian Whitehouse, Julie Aspden, Ian Carr, BBSRC (May 2016), £466,043
Peter Urwin, BBSRC (May 2016), £432,379
John Trinick, Elwyn Issac, Leverhulme Trust
(May 2016), £171,742
, British Council, UK
(May 2016), £11,100
Mark Harris, Horserace Betting Levy Board
(Apr 2016), £10,000
Peter Stockley, Neil Ranson, Roman Tuma, David Rowlands, MRC (Apr 2016), £341,225
Jamel Mankouri, Royal Society (Apr 2016), £332,396
Andrew Tuplin, MRC (Apr 2016), £508,170